Normal view MARC view ISBD view

Programmed Death Ligand 1: A Step toward Immunoscore for Esophageal Cancer.

MedStar author(s):

Citation: Annals of Thoracic Surgery. 2018 May 30PMID: 29859152Institution: MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment: Pathology | Surgery/Thoracic and Esophageal SurgeryForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 2018 Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:

0003-4975

Name of journal: The Annals of thoracic surgeryAbstract: BACKGROUND: To evaluate the effect of tumor infiltrating lymphocyte (TIL) density and programmed death ligand 1 (PD-L1) expression on the prognosis of esophageal cancer.CONCLUSIONS: Positive staining for PD-L1 may be a prognostic marker for decreased survival in esophageal adenocarcinoma. Additional TIL cell types should be investigated for creation of an esophageal cancer Immunoscore. PD-L1 has potential as a therapeutic target.Copyright (c) 2018. Published by Elsevier Inc.METHODS: Banked tissue specimens from 53 patients who underwent esophagectomies for malignancy at a single institution over a 6-year period were stained for cluster of differentiation 3 (CD3), cluster of differentiation 8 (CD8) and PD-L1. Tumors were characterized as staining high or low density for CD3 and CD8, as well as positive or negative for PD-L1. TIL density and PD-L1 expression were analyzed in the context of survival, recurrence and perioperative characteristics.RESULTS: Median follow up was 823 days with 92.5% survival and 26.8% recurrence. All were adenocarcinomas. Neoadjuvant chemotherapy was given in 56.6%, neoadjuvant radiotherapy given in 37.7%. High CD3 density was found in 83% while high CD8 density was found in 56.6%. 18.9% of tumors stained positive for PD-L1. Survival was significantly shorter in Kaplan-Meier analysis for patients with primary tumors staining positive for PD-L1 (Log rank: P=0.05). Multivariable analysis controlling for neoadjuvant therapy, TIL markers, PD-L1, age and sex found no significant difference in recurrence or survival.All authors: Chahine JJ, Desale S, Haddad NG, Hynes CF, Iwamoto A, Kallakury BV, Kwon DH, Lofthus A, Margolis M, Marshall MB, Vadlamudi C, Watson TJFiscal year: FY2018Digital Object Identifier:

https://dx.doi.org/10.1016/j.athoracsur.2018.05.002

Date added to catalog: 2018-06-19

Holdings ( 1 )
Title notes ( 7 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	29859152	Available		29859152

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

BACKGROUND: To evaluate the effect of tumor infiltrating lymphocyte (TIL) density and programmed death ligand 1 (PD-L1) expression on the prognosis of esophageal cancer.

CONCLUSIONS: Positive staining for PD-L1 may be a prognostic marker for decreased survival in esophageal adenocarcinoma. Additional TIL cell types should be investigated for creation of an esophageal cancer Immunoscore. PD-L1 has potential as a therapeutic target.

METHODS: Banked tissue specimens from 53 patients who underwent esophagectomies for malignancy at a single institution over a 6-year period were stained for cluster of differentiation 3 (CD3), cluster of differentiation 8 (CD8) and PD-L1. Tumors were characterized as staining high or low density for CD3 and CD8, as well as positive or negative for PD-L1. TIL density and PD-L1 expression were analyzed in the context of survival, recurrence and perioperative characteristics.

RESULTS: Median follow up was 823 days with 92.5% survival and 26.8% recurrence. All were adenocarcinomas. Neoadjuvant chemotherapy was given in 56.6%, neoadjuvant radiotherapy given in 37.7%. High CD3 density was found in 83% while high CD8 density was found in 56.6%. 18.9% of tumors stained positive for PD-L1. Survival was significantly shorter in Kaplan-Meier analysis for patients with primary tumors staining positive for PD-L1 (Log rank: P=0.05). Multivariable analysis controlling for neoadjuvant therapy, TIL markers, PD-L1, age and sex found no significant difference in recurrence or survival.

English